Market Overview

UPDATE: Sterne Agee Downgrades PAREXEL Following FY13 Results, FY14 Guidance

Share:
Related PRXL
Deutsche Bank's Top 20 'Best Buy Ideas'
Top 4 NASDAQ Stocks In The Medical Laboratories & Research Industry With The Highest EPS

In a report published Wednesday, Sterne Agee analyst Greg T. Bolan downgraded PAREXEL (NASDAQ: PRXL) from Neutral to Underperform, and lowered the price target from $44.00 to $36.00.

In the report, Sterne Agee noted, “After rigorous yet straightforward analyses, we conclude that PRXL's FY13 results were inflated by several favorable, non-fundamental variables and that FY14 operating margin guidance appears aggressive. We also conclude that with the expected moderation of revenue contribution from PRXL's largest client, upside to FY14 revenue guidance may be limited. Downgrading to Underperform and establishing a $36 price target based on 16x our CY15 EPS estimate of $2.36.”

PAREXEL closed on Tuesday at $51.33.

Latest Ratings for PRXL

DateFirmActionFromTo
Feb 2015CitigroupMaintainsBuy
Jan 2015Deutsche BankMaintainsHold
Jan 2015SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for PRXL
View the Latest Analyst Ratings

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Downgrades Analyst Ratings

 

Related Articles (PRXL)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content